<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Stem cell transplantation for <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is characterized by high transplant-related mortality (TRM), especially in older patients and those with more advanced disease </plain></SENT>
<SENT sid="1" pm="."><plain>Outcome after peripheral blood stem cell transplantation (PBSCT) may be superior to earlier results with bone marrow transplantation </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-three patients (aged 12-73 years; median, 49 years) received an HLA-identical sibling donor PBSCT </plain></SENT>
<SENT sid="3" pm="."><plain>Twenty three patients aged &lt; or =55 years without prohibitive comorbidity received myeloablative total body irradiation-based conditioning, followed by a T cell-depleted PBSCT and delayed add-back of donor lymphocytes </plain></SENT>
<SENT sid="4" pm="."><plain>Older patients or those with comorbidities (n = 20) received reduced-intensity conditioning and an unmanipulated PBSCT </plain></SENT>
<SENT sid="5" pm="."><plain>Thirty-seven (86%) had advanced disease (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts [n = 9], <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts in transformation [n = 6], <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> [n = 13], or treatment-related <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> [n = 9]); 6 had low-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> or <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo>) </plain></SENT>
<SENT sid="6" pm="."><plain>The median follow-up was 18 months (range, 5-89 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Actuarial probabilities of 3-year overall survival (OS), disease-free survival, relapse, and TRM were 64%, 59%, 26%, and 23%, respectively, for 34 primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>The best results were in 19 patients younger than 50 years of age undergoing myeloablative PBSCT (actuarial probabilities of OS, disease-free survival, relapse, and TRM were 81%, 72%, 22%, and 7%, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Although outcomes for <z:hpo ids='HP_0000001'>all</z:hpo> stages of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were improved, that for <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> remained dismal, with 11% OS, because of a high relapse rate (89%) </plain></SENT>
</text></document>